vTv Therapeutics (Nasdaq: VTVT) swings to H1 2026 profit amid T1D trial progress
Rhea-AI Filing Summary
vTv Therapeutics reported second quarter 2026 results and updates on its type 1 diabetes program. For the three months ended June 30, 2026, the company recorded a net loss attributable to shareholders of $13.1 million, or $(1.05) per basic and diluted share, with R&D expenses of $8.8 million and G&A expenses of $5.2 million. No revenue was recognized in the quarter.
For the six months ended June 30, 2026, vTv reported revenue of $36,839 (in thousands) and net income attributable to vTv of 11,080 (in thousands), compared with no revenue and a net loss in the prior-year period. Cash and cash equivalents were $86,643 (in thousands) as of June 30, 2026, and the company expects its cash to fund operations through the anticipated topline data readout from the Phase 3 CATT1 trial of cadisegliatin. Enrollment in CATT1 is expected to complete in the third quarter of 2026, a Phase 2a Hybrid CATT1 trial is planned to start before year end 2026, and a Key Opinion Leader event on cadisegliatin and type 1 diabetes is planned for the fourth quarter of 2026.
Positive
- Six-month 2026 turnaround to profit: Revenue of $36,839 (in thousands) in the first half of 2026 generated net income of 11,080 (in thousands), compared with no revenue and a net loss in the prior-year period.
- Cash runway through key Phase 3 data: Cash and cash equivalents of $86,643 (in thousands) as of June 30, 2026, are expected to fund operations through the anticipated topline readout of the Phase 3 CATT1 trial.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Cash and cash equivalents: $86,643 (in thousands)
Revenue: $36,839 (in thousands)
R&D expenses: $8,770 (in thousands)
+5 more
8 metrics
Cash and cash equivalents
$86,643 (in thousands)
As of June 30, 2026
Revenue
$36,839 (in thousands)
Six months ended June 30, 2026
R&D expenses
$8,770 (in thousands)
Three months ended June 30, 2026
G&A expenses
$5,160 (in thousands)
Three months ended June 30, 2026
Net loss
$13.1 million
Three months ended June 30, 2026, attributable to vTv shareholders
Net income
11,080 (in thousands)
Six months ended June 30, 2026, attributable to vTv Therapeutics Inc.
Contract liabilities
$1,830 (in thousands)
As of June 30, 2026
Total stockholders’ equity
$78,632 (in thousands)
As of June 30, 2026
Key Terms
Phase 3 CATT1 trial, Breakthrough Therapy designation, hybrid closed-loop insulin delivery systems, glucokinase activator, +1 more
5 terms
Phase 3 CATT1 trial medical
"Enrollment in the ongoing Phase 3 CATT1 trial evaluating cadisegliatin"
Breakthrough Therapy designation regulatory
"Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration"
A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.
hybrid closed-loop insulin delivery systems medical
"participants using hybrid closed-loop insulin delivery systems to inform the design"
glucokinase activator medical
"cadisegliatin, a potential first-in-class oral glucokinase activator being investigated"
A glucokinase activator is a drug that boosts the activity of glucokinase, an enzyme that helps the liver and pancreas sense and lower blood sugar. Think of it as turning up the sensitivity of the body’s sugar thermostat so insulin release and sugar storage respond more effectively; for investors, these drugs matter because they can become new diabetes treatments with sizable market potential while carrying typical development, safety and regulatory risks that affect a company’s value.
contract liabilities financial
"Contract liabilities | 1,830 | | | 18,669"
Contract liabilities are amounts a company has been paid in advance for goods or services it still owes to customers — think of them like gift cards or prepaid subscriptions the company must fulfill later. For investors, they show promised future work or deliveries that will turn into revenue over time, reveal cash already collected, and help assess whether a firm has a backlog of obligations that could affect future earnings and cash flow.
Earnings Snapshot
Q2 2026 net loss attributable to shareholders: $13.1 million
quarter and six months ended June 30, 2026
Q2 2026 net loss attributable to shareholders
$13.1 million
$6.0 million net loss in Q2 2025
H1 2026 revenue
$36,839 (in thousands)
no revenue in H1 2025
H1 2026 net income attributable to vTv Therapeutics Inc.
11,080 (in thousands)
$11,138 (in thousands) net loss in H1 2025
Cash and cash equivalents
$86,643 (in thousands) as of June 30, 2026
$88,932 (in thousands) as of December 31, 2025
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What were vTv Therapeutics (VTVT) key financial results for Q2 2026?
vTv reported a Q2 2026 net loss attributable to shareholders of $13.1 million, or $(1.05) per share. Research and development expenses were $8.8 million, and general and administrative expenses were $5.2 million, reflecting continued investment in the cadisegliatin clinical program and corporate operations.
How did vTv Therapeutics (VTVT) first-half 2026 performance compare with 2025?
In the six months ended June 30, 2026, vTv generated revenue of $36,839 (in thousands) and net income of 11,080 (in thousands). In the same period of 2025, the company reported no revenue and a net loss of 11,138 (in thousands), indicating a major year-over-year improvement.
What is the status of the Phase 3 CATT1 trial for vTv Therapeutics (VTVT)?
The Phase 3 CATT1 trial evaluating cadisegliatin as an oral adjunctive therapy to insulin in type 1 diabetes is ongoing. Enrollment is expected to be completed in the third quarter of 2026, with topline data anticipated thereafter based on company disclosures.
What is vTv Therapeutics (VTVT) cash position and runway as of June 30, 2026?
As of June 30, 2026, vTv held cash and cash equivalents of $86,643 (in thousands). Based on this position, the company expects it has sufficient cash to fund operations through the anticipated topline data readout from the Phase 3 CATT1 trial of cadisegliatin.
What upcoming milestones and events has vTv Therapeutics (VTVT) highlighted?
vTv expects to complete CATT1 enrollment in Q3 2026, initiate the Phase 2a Hybrid CATT1 trial before year end 2026, and host a Key Opinion Leader event in Q4 2026 focused on type 1 diabetes, hypoglycemia burden, and cadisegliatin’s potential.
What is cadisegliatin, vTv Therapeutics (VTVT) lead candidate, and its regulatory status?
Cadisegliatin (TTP399) is a novel oral, liver-selective glucokinase activator being investigated as an adjunctive treatment for type 1 diabetes. It has received Breakthrough Therapy designation from the U.S. FDA, although its safety and efficacy remain under investigation and are not yet established.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (date of earliest event reported): August 6, 2026
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File No.) | (IRS Employer Identification No.) | ||||||
(Address of principal executive offices)
(336 ) 841-0300
(Registrant’s telephone number, including area code)
NOT APPLICABLE
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 Results of Operations and Financial Condition
On August 6, 2026, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal period ended June 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.
The information in this report (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d)Exhibits
| Exhibit No. | Description | |||||||
| 99.1 | Press Release dated August 6 2026, announcing financial results for the fiscal quarter ended June 30, 2026 | |||||||
| 104 | Cover Page Interactive Data File (embedded within Inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| VTV THERAPEUTICS INC. | |||||||||||
| By: | /s/ Paul J. Sekhri | ||||||||||
| Name: | Paul J. Sekhri | ||||||||||
| Title: | President and Chief Executive Officer | ||||||||||
Dated: August 6, 2026
Exhibit 99.1
vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to complete enrollment in third quarter of 2026
Cadisegliatin Phase 2a hybrid closed-loop trial (Hybrid CATT1) in T1D to initiate before year end 2026
Strong balance sheet expected to fund operations through anticipated CATT1 topline data readout
Company to host Key Opinion Leader (KOL) event in the fourth quarter of 2026 highlighting cadisegliatin and its potential in people with T1D
HIGH POINT, N.C., August 6, 2026 (GLOBE NEWSWIRE) – vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update. The Company expects to complete enrollment in the Phase 3 CATT1 trial in the third quarter of 2026. Based on its current cash position at the end of the second quarter of 2026, vTv expects to have sufficient cash to fund operations through the anticipated CATT1 topline data readout. In the fourth quarter of 2026, the Company also plans to host a Key Opinion Leader (KOL) event focused on T1D, the burden of managing hypoglycemia without compromising glycemic control, and cadisegliatin’s potential to address this significant unmet need.
“Cadisegliatin has been specifically designed to address the significant unmet need of hypoglycemia, a major limiting factor in achieving optimal blood glucose control in T1D," said Paul Sekhri, Chairman, President, and CEO of vTv Therapeutics. "We look forward to discussing cadisegliatin’s potential with leading experts in T1D at our planned fourth-quarter KOL event. With cash runway through our anticipated topline data readout, we are focused on advancing development of the potential first oral adjunctive therapy for people with T1D.”
Recent Company Highlights
•CATT1 Trial Advancing. Enrollment in the ongoing Phase 3 CATT1 trial evaluating cadisegliatin as an oral adjunctive therapy to insulin in individuals with T1D is expected to be completed in the third quarter of 2026.
•KOL Event on Cadisegliatin Program. In the fourth quarter of 2026, the Company plans to host a KOL event focused on T1D, the significant unmet medical need of hypoglycemia, and the cadisegliatin Phase 3 clinical program.
•Cadisegliatin Hybrid Closed-Loop Trial (Hybrid CATT1). vTv expects to initiate the Phase 2a Hybrid CATT1 trial before year end 2026. This randomized, double-blind, crossover, multicenter study will evaluate cadisegliatin in T1D participants using hybrid closed-loop insulin delivery systems to inform the design and operational aspects of future Phase 3 research in this population.
Second Quarter 2026 Financial Results
•Cash Position: Cash and cash equivalents as of June 30, 2026, were $86.6 million compared to $88.9 million as of December 31, 2025.
•Research & Development (R&D) Expenses: R&D expenses were $8.8 million and $4.1 million for the three months ended June 30, 2026, and 2025, respectively. The increase was primarily driven by continued investment in the Phase 3 CATT1 trial.
•General & Administrative (G&A) Expenses: G&A expenses were $5.2 million and $3.6 million for the three months ended June 30, 2026, and 2025, respectively. The increase reflects ongoing support for corporate operations and clinical development activities.
•Interest Income: Interest income for the three months ended June 30, 2026, and 2025, of $0.8 million and $0.3 million, respectively, was related to dividend income from the Company's money market accounts.
•Net Loss: Net loss attributable to vTv shareholders for the three months ended June 30, 2026, was $13.1 million or $1.05 per basic and diluted share. Net loss attributable to vTv shareholders for the comparable period a year ago was $6.0 million or $0.92 per basic and diluted share.
Upcoming Events
•H.C. Wainwright 28th Annual Global Investment Conference
Format: Fireside Presentation and 1x1 Investor Meetings
Location: New York, NY
Date: September 14-16, 2026
•5th Annual ROTH Healthcare Opportunities Conference
Format: 1x1 Investor Meetings
Location: New York, NY
Date: September 29, 2026
vTv Therapeutics Inc.
Condensed Consolidated Balance Sheets
(in thousands)
| June 30, 2026 | December 31, 2025 | ||||||||||
| (Unaudited) | |||||||||||
| Assets | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 86,643 | $ | 88,932 | |||||||
| Prepaid expenses | 416 | 743 | |||||||||
| Other current assets | 530 | 218 | |||||||||
| Total current assets | 87,589 | 89,893 | |||||||||
| Other assets | 4 | 6 | |||||||||
| Total assets | $ | 87,593 | $ | 89,899 | |||||||
| Liabilities and Stockholders’ Equity | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable and accrued expenses | $ | 6,992 | $ | 6,557 | |||||||
| Warrant liability, related party | 25 | 84 | |||||||||
| Total current liabilities | 7,017 | 6,641 | |||||||||
| Contract liabilities | 1,830 | 18,669 | |||||||||
| Warrant liability | 114 | 152 | |||||||||
| Total liabilities | 8,961 | 25,462 | |||||||||
| Commitments and contingencies | |||||||||||
| Stockholders’ equity: | |||||||||||
| Class A Common Stock | 39 | 39 | |||||||||
| Class B Common Stock | — | — | |||||||||
| Additional paid-in capital | 394,205 | 391,090 | |||||||||
| Accumulated deficit | (315,612) | (326,692) | |||||||||
| Total stockholders’ equity | 78,632 | 64,437 | |||||||||
| Total liabilities and stockholders’ equity | $ | 87,593 | $ | 89,899 | |||||||
vTv Therapeutics Inc.
Condensed Consolidated Statements of Operations
(in thousands, except per share data)
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| (Unaudited) | (Unaudited) | ||||||||||||||||||||||
| Revenue | $ | — | $ | — | $ | 36,839 | $ | — | |||||||||||||||
| Operating expenses: | |||||||||||||||||||||||
| Research and development | 8,770 | 4,103 | 17,748 | 6,933 | |||||||||||||||||||
| General and administrative | 5,160 | 3,618 | 9,758 | 7,291 | |||||||||||||||||||
| Total operating expenses | 13,930 | 7,721 | 27,506 | 14,224 | |||||||||||||||||||
| Operating (loss) income | (13,930) | (7,721) | 9,333 | (14,224) | |||||||||||||||||||
| Interest income | 812 | 275 | 1,650 | 606 | |||||||||||||||||||
Other income (expense), net | 64 | 66 | 97 | 21 | |||||||||||||||||||
| Net (loss) income before income taxes and noncontrolling interest | (13,054) | (7,380) | 11,080 | (13,597) | |||||||||||||||||||
| Income tax provision | — | — | — | — | |||||||||||||||||||
| Net (loss) income before noncontrolling interest | (13,054) | (7,380) | 11,080 | (13,597) | |||||||||||||||||||
| Less: net loss attributable to noncontrolling interest | — | (1,334) | — | (2,459) | |||||||||||||||||||
| Net (loss) income attributable to vTv Therapeutics Inc. | $ | (13,054) | $ | (6,046) | $ | 11,080 | $ | (11,138) | |||||||||||||||
| Net (loss) income attributable to vTv Therapeutics Inc. common shareholders | $ | (13,054) | $ | (6,046) | $ | 11,080 | $ | (11,138) | |||||||||||||||
| Basic net (loss) income per share of vTv Therapeutics Inc. Class A common stock | $ | (1.05) | $ | (0.92) | $ | 0.89 | $ | (1.69) | |||||||||||||||
| Basic weighted average number of vTv Therapeutics Inc. Class A common stock | 12,409,316 | 6,587,070 | 12,409,297 | 6,584,969 | |||||||||||||||||||
| Diluted net (loss) income per share of vTv Therapeutics Inc. Class A common stock | $ | (1.05) | $ | (0.92) | $ | 0.76 | $ | (1.69) | |||||||||||||||
| Diluted weighted average number of vTv Therapeutics Inc. Class A common stock | 12,409,316 | 6,587,070 | 14,541,788 | 6,584,969 | |||||||||||||||||||
About vTv Therapeutics
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv's clinical pipeline is led by cadisegliatin, a potential first-in-class oral glucokinase activator being investigated in a U.S. Phase 3 study for the treatment of T1D. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.
About Cadisegliatin
Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated in the U.S. as a potential first-in-class oral adjunctive treatment for T1D. In non-clinical studies, cadisegliatin acted selectively on the liver and increased the activity of glucokinase independently from insulin. These studies support clinical investigation of whether cadisegliatin can improve glycemic control through hepatic glucose uptake and glycogen storage. Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).
Cadisegliatin is under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.
Forward-Looking Statements
This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case,
their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, the anticipated effect of Phase 3 topline data on the Company, the benefits of cadisegliatin to people living with T1D, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures, or investments we may undertake. We qualify all our forward-looking statements by these cautionary statements.
Investor Contact
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com
Media Contact
Caren Begun
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com